BioCardia Reports 2020 Financial Results and Recent Business Highlights
March 30, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative...
BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
March 15, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces...
BioCardia Signs Agreement With Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates
February 23, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese pharmaceutical company related to...
BioCardia Announces Clinical Leadership Changes
February 17, 2021 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioCardia Update on Cell Therapy Product Development and 2021 Milestones
February 02, 2021 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides...
Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors
January 11, 2021 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes...
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies
December 30, 2020 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
December 17, 2020 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that...
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights
November 10, 2020 07:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and...
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
October 26, 2020 07:30 ET
|
BioCardia, Inc.
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months SAN CARLOS, Calif., Oct. 26, 2020 (GLOBE...